Please assess the completion status of the following clinical trial:

Trial Title: Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 6 weeks of age (range: 42-48 days).~* Parents that consent for participation in the full length of the study.~* Parents that are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of IPV or collection of blood by venipuncture.~* Acute diarrhea, infection or illness at the time of enrollment (6 weeks of age) that would require infant's admission to a hospital.~* Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit (6 weeks of age).~* Evidence of a chronic medical condition identified by a study medical officer during physical exam.~* Receipt of any polio vaccine (OPV or IPV) before enrollment based upon documentation or parental recall.~* Receipt of any rotavirus vaccine (RV1 or RV5) before enrollment based upon documentation or parental recall.~* Known allergy/sensitivity or reaction to polio or rotavirus vaccine, or contents of polio or rotavirus vaccine.~* Infants from multiple births. Infants from multiple births will be excluded because the infant(s) who is/are not enrolled would likely receive OPV through routine immunization and transmit vaccine poliovirus to the enrolled infant.~* Infants from premature births (\<37 weeks of gestation).~* History of intussusception, intestinal malformations, or abdominal surgery.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 6 Weeks
- Healthy Volunteers: t

Study Arms:
- IPV at 14 and 22 weeks of age, Rotarix (Type: ACTIVE_COMPARATOR): Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
- IPV at 14 and 22 weeks of age, RotaTeq (Type: ACTIVE_COMPARATOR): Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
- IPV at 14 and fIPV at 22 weeks, Rotarix (Type: ACTIVE_COMPARATOR): Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
- IPV at 14 and fIPV at 22 weeks, RotaTeq (Type: ACTIVE_COMPARATOR): Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
- IPV at 6 and fIPV at 22 weeks, Rotarix (Type: ACTIVE_COMPARATOR): Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
- IPV at 6 and fIPV at 22 weeks, RotaTeq (Type: ACTIVE_COMPARATOR): Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
- fIPV at 6-14-22 weeks of age, Rotarix (Type: ACTIVE_COMPARATOR): Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
- fIPV at 6-14-22 weeks of age, RotaTeq (Type: ACTIVE_COMPARATOR): Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).